Şeyma Yıldız

Şeyma Yıldız

Auto-generated profile, based on publicly available information

Şeyma Yıldız

Department of Internal Medicine , Kayseri City Hospital , Kayseri , Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
BABanu Açmaz
Banu Açmaz
SBSami Bahçebaşı
Sami Bahçebaşı
EAErdem Aydın
Erdem Aydın
ŞYŞeyma Yıldız
Şeyma Yıldız
İBİfakat İrem Biçer
İfakat İrem Biçer
Introduction: Obesity, particularly morbid obesity, is associated with significant metabolic alterations such as insulin resistance and compensatory hyperinsulinemia. These pathophysiological changes may influence the performance and interpretation of glycemic diagnostic tools, including the oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c). This study is aimed at comparing the diagnostic profiles of OGTT and HbA1c across BMI categories, with a specific focus on morbid obesity and the potential role of elevated insulin levels in test discrepancies. Materials and Methods: This retrospective study included 1031 patients who were classified into nonobese, obese, and morbidly obese groups based on body mass index (BMI). All participants underwent assessment of glycemic status, lipid profile, and related metabolic parameters. Results: Of the study population, 86.8% were female. Based on BMI classification, 56.5% were obese, 35.8% morbidly obese, and 7.8% nonobese. The prevalence of dysglycemia (prediabetes + diabetes) was 43.1% according to HbA1c and 30.9% according to OGTT. Dysglycemia was significantly more frequent in the morbidly obese group by HbA1c ( p < 0.001), while OGTT showed no significant intergroup difference ( p = 0.117). The agreement between methods was low ( κ = 0.326). HbA1c, insulin, HOMA‐IR, CRP, and triglyceride levels increased with BMI. Insulin‐related parameters were higher among HbA1c‐defined dysglycemic individuals. Discussion: HbA1c may be more sensitive in identifying early metabolic disturbances, particularly during the compensatory phase involving hyperinsulinemia. Elevated insulin levels may attenuate glucose response during OGTT, potentially reducing its diagnostic sensitivity.

21 October 2020 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Open access
PDF file
UTUlaş Serkan Topaloğlu
Ulaş Serkan Topaloğlu
HTHatice Kayış Topaloğlu
Hatice Kayış Topaloğlu
MKMelih KIZILTEPE
Melih KIZILTEPE
MKMesut Kılıç
Mesut Kılıç
SBSami Bahçebaşı
Sami Bahçebaşı
YŞYasin Şimşek
Yasin Şimşek
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p<0.001). There was also a significant decrease in mean, daily insulin dose, weight and BMI values of patients via IDegAsp. While there was an increase in the amount of dipeptidyl peptidase 4-inhibitors (DPP4-i) and sodium-glucose co-transporter 2-inhibitors (SGLT2-i), there was a decrease in daily injection frequency. There was also a significant decrease in the median values of monthly hypoglycemia rate (from 2.0 to 1.0, p<0.001) and the entire HFS scores (HFS-T: from 1.09 to 0.73, p<0.001; HFS-B: from 0.83 to 0.60, p<0.001; HFS-W: from 1.33 to 0.88, p<0.001). There was a strong positive correlation between ΔHFS-B and daily injection frequency (Rho: 0.398; P: 0.016). Conclusions: IDegAsp co-formulation, combined with DPP4-i and/or SGLT2-i, can provide usefulness in terms of rates of hypoglycemia, reduced HbA1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.

23 December 2020 in Drug Metabolism and Drug Interactions
Verified
Journal Article
Open access
PDF file
UTUlaş Serkan Topaloğlu
Ulaş Serkan Topaloğlu
HTHatice Kayış Topaloğlu
Hatice Kayış Topaloğlu
MKMelih KIZILTEPE
Melih KIZILTEPE
MKMesut Kılıç
Mesut Kılıç
SBSami Bahçebaşı
Sami Bahçebaşı
YŞYasin Şimşek
Yasin Şimşek
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p<0.001). There was also a significant decrease in mean, daily insulin dose, weight and BMI values of patients via IDegAsp. While there was an increase in the amount of dipeptidyl peptidase 4-inhibitors (DPP4-i) and sodium-glucose co-transporter 2-inhibitors (SGLT2-i), there was a decrease in daily injection frequency. There was also a significant decrease in the median values of monthly hypoglycemia rate (from 2.0 to 1.0, p<0.001) and the entire HFS scores (HFS-T: from 1.09 to 0.73, p<0.001; HFS-B: from 0.83 to 0.60, p<0.001; HFS-W: from 1.33 to 0.88, p<0.001). There was a strong positive correlation between ΔHFS-B and daily injection frequency (Rho: 0.398; P: 0.016). Conclusions: IDegAsp co-formulation, combined with DPP4-i and/or SGLT2-i, can provide usefulness in terms of rates of hypoglycemia, reduced HbA1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.